Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces that it will host its first European Key Opinion Leader (KOL) Advisory Panel meeting ahead of the 21st Congress of the ESSM on 14-16 February 2019, at Cultural and Congress Centre Cankarjev Dom, Ljubljana, Slovenia. This meeting follows the successful US KOL Advisory Panel meeting at the Sexual Medicine Society of North America (SMSNA) in November 2018.
As announced on 28 January 2019, Tim Holland, Director of Clinical Development at Futura Medical, will be presenting safety data in female partners on its lead product MED2005, a topical glyceryl trinitrate (“GTN”) gel for the treatment of erectile dysfunction (“ED”) at the ESSM. The poster entitled “Establishing the safety profile in sexual partners of a new topical glyceryl trinitrate gel for the treatment of erectile dysfunction“ on Thursday 14 February at 15.30 CET. The presentation will be part of the “Male sexual dysfunction: medical treatment” poster session held in Foyer 1, Floor 1.